[Edaily Reporter KIM EUNG-TAE ] Global beauty company APR(278470)has scientifically proven the potential efficacy of its beauty devices in treating hair loss using its core technology. APR plans to expand the research results from its high-frequency devices into platform technologies applicable across the fields of hair, scalp, and hair loss.

APR announced on the 13th that research findings—conducted through a joint industry-academia project—regarding the improvement of scalp health and the treatment of androgenetic alopecia using radiofrequency (RF) microporation technology have been published in the international academic journal *Pharmaceutics*.
The research team utilized the radiofrequency microporation technology applied to the “Air Shot” mode of APR’s home beauty DEVICE, the “Medicube Age R Booster Pro X2,” to evaluate, using an animal model, the extent to which the skin delivery of topically applied minoxidil (MNX) and its hair regeneration effects were enhanced. High-frequency microporation is a technology that uses precisely controlled high-frequency energy to form temporary micro-channels in the scalp’s stratum corneum, thereby helping the active ingredients in topical formulations to be absorbed more efficiently into the skin.
According to preclinical study results, when high-frequency microporation was used in combination with minoxidil, the amount of minoxidil deposited in the epidermis and dermis increased by up to 2.4 times compared to application alone. Furthermore, in an animal model of androgenetic alopecia, hair coverage, length, and thickness showed significant improvements.
The company explains that since this technology technically overcomes the delivery limitations of existing topical treatments, it is expected to serve as a new alternative for women and others who face restrictions on taking oral hair loss medications. Oral treatments containing finasteride—widely used for male-pattern hair loss—are strictly prohibited for women of childbearing age due to risks such as fetal malformations in male fetuses. Consequently, minoxidil, applied directly to the scalp, is recommended as the most common drug treatment for female-pattern hair loss. However, topical treatments like minoxidil have the drawback of not penetrating sufficiently into the skin and the area around hair follicles; therefore, ensuring that the active ingredient reaches the target site in adequate amounts has been identified as a key area for improvement.
APR plans to continuously verify the applicability, efficacy, and safety of this platform technology in the field of hair loss treatment through additional clinical studies in the future, and to establish a new paradigm in the scalp and hair care market by securing sufficient clinical evidence. An APR official stated, “We will continue to accelerate the development of new technologies based on our differentiated R&D competitiveness and strive to introduce innovative products that incorporate these advancements.”
Meanwhile, APR is expanding its business scope into the hair care market, building on its existing cosmetics business. As demand for hair care products becomes increasingly evident in global markets such as the United States, the company’s strategy is to cultivate hair care products as a new growth engine.